Neurocysticercosis and seizures: Avoiding the cost of antihelminthic treatment

Neurology

Volumn 59, Issue 11, 2002, Pages 1669-

  Davis, Larry E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHELMINTIC AGENT;

CESTODE; CIRCULATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST; CYST; DEGENERATION; ENDEMIC DISEASE; EPILEPSY; FECES; GASTROINTESTINAL TRACT; GRAY MATTER; HUMAN; IMMIGRATION; INFLAMMATION; NEUROCYSTICERCOSIS; NOTE; OOCYTE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RURAL AREA; SEIZURE; TAENIA SOLIUM; UNITED STATES; WHITE MATTER; WORM INFECTION;

EID: 0037058755     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (3)

1. Pal DK, Carpio A, Sander JWAS. Neurocysticercosis and epilepsy in developing countries. J Neurol Neurosurg Psychiatry 2000;68:137-143.
2. Davis LE, Kornfeld M. Neurocysticercosis: Neurologic, pathogenic, diagnostic and therapeutic aspects. Eur Neurol 1991;31:229-240.
3. Salinas R, Prasad K. Drugs for treating neurocysticercosis (tapeworm infection of the brain) [Cochrane Review]. Cochrane Database Syst Rev 2000;(2):CD000215.